Moderate

Thrombocytosis work-up

thrombocytosis w/u · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A high platelet count is far more often reactive (infection, inflammation, iron deficiency, malignancy) than clonal. The work-up separates reactive thrombocytosis from a myeloproliferative neoplasm such as essential thrombocythaemia.

Red flags

  • Thrombosis or TIA/stroke
  • Extreme thrombocytosis (>1000-1500 x10^9/L) with bleeding (acquired von Willebrand)
  • Splanchnic vein thrombosis
  • Weight loss / anaemia suggesting occult malignancy
  • Erythromelalgia with ischaemia

Assessment

Differential diagnosis

  • Reactive (infection, inflammation, surgery, trauma)
  • Iron deficiency
  • Essential thrombocythaemia
  • Other myeloproliferative neoplasms (PV, CML, MF)
  • Post-splenectomy / hyposplenism
  • Occult malignancy

Investigations

  • FBC trend and blood film
  • CRP/ESR and ferritin (reactive causes)
  • JAK2 V617F; CALR and MPL if JAK2 negative
  • BCR::ABL1 to exclude CML
  • Bone marrow if clonal disorder suspected
  • Imaging/assessment for occult malignancy if clinically indicated

Management

  • Confirm the platelet count is genuinely and persistently raised
  • Review for obvious reactive causes: infection, inflammation, bleeding, surgery, iron deficiency
  • Check ferritin and inflammatory markers
  • If no reactive cause or features suggest clonality, test JAK2 V617F
  • If JAK2 negative, test CALR and MPL mutations and exclude CML with BCR::ABL1
  • Examine the film and consider marrow for essential thrombocythaemia diagnosis
  • Risk-stratify essential thrombocythaemia for thrombosis (age, prior thrombosis, JAK2, cardiovascular risk)
  • Treat reactive thrombocytosis by addressing the cause - cytoreduction is not needed
  • For essential thrombocythaemia give aspirin and cytoreduction in high-risk patients
  • Monitor for thrombotic/haemorrhagic complications and disease evolution

Drugs & doses

Aspirin 75-100 mg PO once daily (essential thrombocythaemia, reduce thrombosis)
Hydroxycarbamide 15-20 mg/kg/day PO (high-risk ET cytoreduction)
Anagrelide or interferon as alternative cytoreductive agents
Treat iron deficiency / reactive cause as appropriate

Disposition

Primary care for clearly reactive causes; haematology for suspected clonal disease and ongoing ET management.

Complications & pitfalls

  • Arterial and venous thrombosis
  • Paradoxical bleeding (acquired von Willebrand syndrome at very high counts)
  • Transformation of ET to myelofibrosis or leukaemia
  • Microvascular symptoms
  • Pregnancy complications in ET

Exam pearls

  • Most thrombocytosis is reactive and needs no cytoreduction
  • Iron deficiency is a common and reversible cause
  • Very high platelet counts can paradoxically cause bleeding via acquired von Willebrand syndrome - caution with aspirin
  • JAK2, CALR and MPL cover most essential thrombocythaemia
  • Always exclude CML with BCR::ABL1

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.